Hyaluronidase news

• 

  19 February 2026

  Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer

  The OrigAMI-4 study shows amivantamab with immunotherapy offers durable antitumor activity in recurrent/metastatic head and neck cancer, improving outcomes over current treatments.
• 

  17 February 2026

  Genmab Releases 2025 Annual Report

  The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
• 

  11 February 2026

  Merck's KEYTRUDA and KEYTRUDA QLEX Approved for PD-L1+ Platinum-Resistant Ovarian Cancer

  FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.
• 

  8 January 2026

  Takeda and Halozyme Collaborate on Vedolizumab

  The partnership aims to enhance vedolizumab delivery for IBD treatment, improving patient care and expanding access with ENHANZE technology.
• 

  17 December 2025

  Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Approval for Faster NSCLC Treatment

  FDA approves RYBREVANT FASPRO™ for EGFR-mutated NSCLC, offering faster, subcutaneous administration with fewer side effects compared to IV delivery.
• 

  15 December 2025

  Janssen's TECVAYLI® and DARZALEX FASPRO® Join FDA's Priority Voucher Program

  TECVAYLI® and DARZALEX FASPRO® show significant survival benefits in multiple myeloma, gaining FDA Breakthrough Therapy Designation and Real-Time Oncology Review.

• 

  6 November 2025

  Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma

  DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
• 

  19 October 2025

  Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer

  Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
• 

  14 October 2025

  Genmab Reports Q3 2025 DARZALEX Sales of $3.67 Billion

  Genmab earns royalties from DARZALEX sales, with $2.09B in the U.S. and $1.58B globally. The company focuses on innovative antibody therapeutics for cancer and serious diseases.
• 

  19 September 2025

  Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use

  CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.